Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy by Myrna Luna-Gutiérrez, Erika Azorín-Vega, Rigoberto Oros-Pantoja, Blanca Ocampo-García, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Gerardo Bravo-Villegas, Clara Santos-Cuevas, Laura Meléndez-Alafort, Guillermina Ferro-Flores

“…Abstract Background Cancer immunotherapy is a relatively new approach to cancer treatment. …”
Get full text

Arginase-1-specific T cells target and modulate tumor-associated macrophages by Mads Hald Andersen, Inés Lecoq, Ayako Wakatsuki Pedersen, Evelina Martinenaite, Shamaila Munir Ahmad, Maria Perez-Penco, Lucia Lara de la Torre, Marion Chapellier, Lars Rønn Olsen, Mia Aaboe-Jørgensen, Hannah Jorinde Glöckner, Anne Mette Askehøj Rømer

“…Background Arginase-1 (Arg1) expressing tumor-associated macrophages (TAMs) may create an immune-suppressive tumor microenvironment (TME), which is a significant challenge for cancer immunotherapy. We previously reported the existence of Arg1-specific memory T cells among peripheral blood mononuclear cells (PBMCs) and described that Arg-1-based immune modulatory vaccines (IMVs) control tumor growth and alter the M1/M2 macrophage ratio in murine models of cancer. …”
Get full text

Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation by Ying Zhu, Jiao Li, Tao Zhang, Lei Zhao, Min Jin, Jinghua Ren, Jing Tang, Haihong Wang, Zhenyu Lin, Qing Liang, Ruiqi Li, Biying Zhang, Qingling Hua, Guojie Xu, Jiayuan Chen, Lanqing Wang, Dejun Zhang, Dandan Yu

“…Furthermore, targeting CEMIP provides an effective strategy for colorectal cancer immunotherapy.…”
Get full text

Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors by Qiang Wang, Qing Yi, Wei Xiong, Rui Duan, Jianfei Qian, Liuling Xiao, Miao Xian, Pan Su, Chuanchao Zhang, Yabo Li, Ling Zhong, Chengyun Zheng

“…Background Cancer immunotherapy using immune checkpoint blockade (ICB) has revolutionized cancer treatment. …”
Get full text

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study by Chenyu Mao, Anwen Xiong, Jiong Qian, Wenxiang Wang, Ying Liu, Tao Zhang, Zhihai Wu, Haiqing Ni, Jia Lu, Sixiang Long, Li Zhao, Yuling Chen, Caicun Zhou, Nong Xu

“…Abstract Background Co-inhibition of immune checkpoints lymphocyte-activation gene 3 (LAG-3) and PD-1 is believed to enhance cancer immunotherapy through synergistic effects. Herein, we evaluate the safety and efficacy of IBI110 (anti-LAG-3 antibody) with sintilimab (an anti-PD-1 antibody) in Chinese patients with advanced solid tumors. …”
Get full text

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma by Leonard D’Amico, Martin Cheever, Steven P Fling, Anna Wright, Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Thomas S Uldrick, Robert Yarchoan, Judith C Kaiser, Angela Shaulov Kask, Manoj P Menon, Paul Couey, Eli Burnham, Allysson Angeldekao, Byung Ha Lee, Li-Lian Kwok, Chia-Ching Jackie Wang

Get full text

SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report by Hongyan Liu, Colleen Callahan, Shannon L Maude, Kevin Owen McNerney, Rebecca M Richards, Paibel Aguayo-Hiraldo, Friso G Calkoen, Julie-An Talano, Amy Moskop, Adriana Balduzzi, Jennifer Krajewski, Hema Dave, Anant Vatsayan, Yimei Li, Kara Lynn Davis

Get full text

RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melan... by Sara Egea‐Rodriguez, Renáta Váraljai, Thierry M. Nordmann, Restuan Lubis, Manuel Philip, Florian Rambow, Alexander Roesch, Michael Flaig, Susanne Horn, Raphael Stoll, Fang Zhao, Annette Paschen, Bert Klebl, Ian D. Hickson, Dirk Schadendorf, Matthias Mann, Iris Helfrich

“…Abstract Background Cancer immunotherapy has transformed metastatic cancer treatment, yet challenges persist regarding therapeutic efficacy. …”
Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

“…Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. …”
Get full text

Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer by Mitchell S. von Itzstein, MD, Jialiang Liu, PhD, Hong Mu-Mosley, PhD, Farjana Fattah, PhD, Jason Y. Park, MD, PhD, Jeffrey A. SoRelle, MD, J. David Farrar, PhD, Mary E. Gwin, MD, David Hsiehchen, MD, Yvonne Gloria-McCutchen, Edward K. Wakeland, PhD, Suzanne Cole, MD, Sheena Bhalla, MD, Radhika Kainthla, MD, Igor Puzanov, MD, MSCI, Benjamin Switzer, DO, MHSA, MS, Gregory A. Daniels, MD, PhD, Yousef Zakharia, MD, Montaser Shaheen, MD, Jianjun Zhang, MD, PhD, Yang Xie, PhD, David E. Gerber, MD

“…Methods: Patients scheduled to receive cancer immunotherapy were enrolled in a multi-institutional prospective biospecimen collection registry. …”
Get full text

Microbial metabolites and immune modulation by Hassan Ghasemi

“…In rheumatoid arthritis, butyrate suppresses Th17-mediated joint inflammation, highlighting its systemic immunomodulatory capabilities. In cancer immunotherapy, SCFAs enhance the efficacy of immune checkpoint inhibitors like anti-PD-1/PD-L1 therapies by reshaping the tumor microenvironment toward an anti-tumoral state. …”
Get full text

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti... by Arndt Borkhardt, Nan Qin, Stephen T Keir, Darell D Bigner, Allison Cole, Matthias Wölfl, Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Joselyn Cruz-Cruz, Claus M Graef, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stühler, Julia Hauer, Thomas Beez, Christiane B Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H Cheshier, Guido Reifenberger, Thomas Kurz, Marc Remke, Siddhartha Mitra

“…Finally, combining CI-994 treatment with an anti-CD47 mAb targeting the CD47-SIRPα phagocytosis checkpoint enhanced in vitro phagocytosis and survival in tumor-bearing mice.Conclusion Together, these findings suggest a dynamic relationship between MYC amplification and innate immune suppression in MYC amplified MB and support further investigation of phagocytosis modulation as a strategy to enhance cancer immunotherapy responses.…”
Get full text

The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy? by Sonja S. Mojsilovic, Slavko Mojsilovic, Victor H. Villar, Juan F. Santibanez

“…Also, new macrophage-based cell therapeutic technologies recently developed using chimeric antigen receptor bioengineering are exposed, which may overcome all solid tumor physical barriers impeding the current adoptive cell therapies and contribute to developing novel cancer immunotherapies.…”
Get full text

MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers by Yixin Yang, Christopher Alderman, Ayoub Sehlaoui, Yuan Xiao, Wei Wang

“…Since the current targeted therapies provide limited benefit to the overall response and survival, there is an urgent need for developing novel therapeutic strategy to improve the outcome of gastroenterological cancers. Immunotherapy has been developed and underwent clinical trials, but displayed limited therapeutic benefit. …”
Get full text

Structural characterization of two γδ TCR/CD3 complexes by Mohammed Hoque, John Benji Grigg, Trudy Ramlall, Jennifer Jones, Luke L. McGoldrick, John C. Lin, William C. Olson, Eric Smith, Matthew C. Franklin, Tong Zhang, Kei Saotome

“…Abstract The T-cell receptor (TCR)/CD3 complex plays an essential role in the immune response and is a key player in cancer immunotherapies. There are two classes of TCR/CD3 complexes, defined by their TCR chain usage (αβ or γδ). …”
Get full text

Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring by Iole Macchia, Valentina La Sorsa, Irene Ruspantini, Massimo Sanchez, Valentina Tirelli, Maria Carollo, Giorgio Fedele, Pasqualina Leone, Giovanna Schiavoni, Carla Buccione, Paola Rizza, Paola Nisticò, Belinda Palermo, Stefania Morrone, Helena Stabile, Aurelia Rughetti, Marianna Nuti, Ilaria Grazia Zizzari, Cinzia Fionda, Roberta Maggio, Cristina Capuano, Concetta Quintarelli, Matilde Sinibaldi, Chiara Agrati, Rita Casetti, Andrea Rozo Gonzalez, Floriana Iacobone, Angela Gismondi, Filippo Belardelli, Mauro Biffoni, Francesca Urbani

“…The panel was based on a backbone mixture of dried antibodies (anti-CD3, anti-CD4, anti-CD8, anti-CD45RA, and anti-CCR7) to detect naïve/memory T cells, recognised as potential prognostic/predictive immunological biomarkers in cancer immunotherapies. The coordinating centre distributed frozen peripheral blood mononuclear cells (PBMCs) and fresh whole blood (WB) samples from healthy donors, reagents, and Standard Operating Procedures (SOPs) to participants who performed experiments by their own equipment, in order to mimic a real-life scenario. …”
Get full text

Differential Regulation of NK Cell Receptors in Acute Lymphoblastic Leukemia by Le Jie Lee, Norfarazieda Hassan, Siti Zuleha Idris, Suresh Kumar Subbiah, Heng Fong Seow, Norhafizah Mohtaruddin, Kian Meng Chang, Raudhawati Osman, Hishamshah Mohd Ibrahim, Sheila Nathan, Maha Abdullah

“…Cancer immunotherapies are preferred over conventional treatments which are highly cytotoxic to normal cells. …”
Get full text

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers by Yongchang Tang, Hong Wang, Jiankun Zhang, Chunhui Yang, Fei Xu, Yan Song, Tianen Li, Qiangbo Zhang

Get full text

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors by Alfred Zippelius, Petra Herzig, Pratiksha Gulati, Christian Klein, Marta Trüb, Kirsten D Mertz, Robert Rosenberg, Viola Heinzelmann-Schwarz, Mark Wiese, Didier Lardinois, Pablo Umana, Marina Natoli, Klas Hatje, Fabian Junker, Zhiwen Jiang, Iakov I Davydov, Markus Germann, Daniel Marbach, Adrian Zwick, Patrick Weber, Stefan Seeber, Lothar Tietze, Laura Codarri-Deak, Henry Kao

“…Background Next-generation cancer immunotherapies are designed to broaden the therapeutic repertoire by targeting new immune checkpoints including lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin and mucin-domain containing-3 (TIM-3). …”
Get full text

Targeting HVEM-GPT2 axis: a novel approach to T cell activation and metabolic reprogramming in non-small cell lung cancer therapy by Yuanshan Yao, Chunji Chen, Bin Li, Wen Gao

“…Abstract Background The modulation of tumor microenvironments through immune checkpoint pathways is pivotal for the development of effective cancer immunotherapies. This study aims to explore the role of HVEM in non-small cell lung cancer (NSCLC) microenvironment. …”
Get full text